Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in
combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma. This
study will help find out if lenvatinib and gefitinib is a safe and useful combination for
treating patients with lenvatinib resistant hepatocellular carcinoma.